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To the Editor: Ischemic peripheral neuropathy is a term used to
escribe the neurological deficits of peripheral nerves in patients
ith peripheral artery obstructive disease (1). Although ischemic
eripheral neuropathy is a major complication of critical limb
schemia resulting in impaired quality of life, effective treatment for
schemic neuropathy is not available at present.
Recently, it has been reported that therapeutic angiogenesis
sing vascular endothelial growth factor (VEGF) gene transfer for
ritical limb ischemia improves ischemic neuropathy in animals (2)
nd humans (3). We reported that therapeutic angiogenesis using
utologous transplantation of bone marrow mononuclear cells
BM-MNCs) for peripheral artery disease increased limb perfu-
ion and improved clinical conditions, such as ischemic pain,
laudication, and ischemic ulcer (4,5). Therefore, we examined
hether autologous transplantation of BM-MNCs would improve
schemic neuropathy with critical limb ischemia in humans.
We enrolled 14 patients with angiographically-proven critical
imb ischemia (Table 1). In each patient, autologous transplanta-
ion of BM-MNCs (4.89  5.21  109 cells) was performed in 1
schemic leg (treated limb), and saline was injected into another leg
control limb). Before and 1 month after transplantation, we
xamined subjective symptoms (visual analogue scale as an index of
est pain severity, pain-free walking distance), ankle brachial
ressure index, and digital subtraction angiography score. Tibial
otor nerve conduction velocity (MNCV), sural sensory nerve
onduction velocity (SNCV), compound muscle action potential
CMAP), tibial and sural sensory nerve action potential (SNAP),
nd quantitative vibration threshold time (QVT) were recorded.
e also measured MNCV, SNCV, CMAP, and SNAP of 23 age-
nd sex-similar healthy subjects. This study was blinded to the
nvestigator who assessed nerve functions. The protocol was
pproved by the institutional ethics committee of Kurume Uni-
ersity. Written informed consent was obtained from all subjects.
Treatment significantly improved subjective symptoms and
eripheral blood perfusion only in the treated limb (Table 1). The
NCV and CMAP could be measured in the treated limb of all
atients, and in the control limb of 12 patients. Before treatment,
oth MNCV and CMAP were significantly smaller in the treated
imb than in the healthy group (Table 1). Treatment significantly
ncreased both MNCV and CMAP only in the treated limb.
reatment recovered MNCV and CMAP to the level of the
ealthy group. The QVT was significantly improved only in the
reated limb, but not in the control limb after treatment (Table 1).
he SNCV and SNAP of the patients did not differ from those of
he healthy group, and the treatment did not affect them (Table 1).
The major findings of this study are as follows. First, autologous
M-MNC transplantation improved subjective ischemic and neu-
opathic symptoms in patients with critical limb ischemia. Second,
he treatment improved not only peripheral blood perfusion but
lso peripheral nerve function. This study confirmed our previousndings (4,5) that autologous BM-MNC transplantation im-
roved ankle brachial pressure index, digital subtraction angiogra-
hy score, and subjective symptoms in treated limbs. Furthermore,
M-MNC transplantation improved objective peripheral nerve
unctions (MNCV, CMAP, and QVT) in the treated limb but not
n the control limb, suggesting that the effects were not related to
atural course or nonspecific effects. Thus, autologous BM-MNC
ransplantation might improve not only peripheral blood perfusion
ut also ischemic peripheral neuropathy.
The improvement of peripheral nerve function may be caused
y better blood perfusion after autologous BM-MNC transplan-
ation. Simovic et al. (3) reported that VEGF gene transfer
mproved the neuropathic symptoms, CMAP, and QVT. They
peculated that the mechanisms of the nerve function improve-
ent were related to the size of the vessels restored by VEGF. In
act, angiogenic cytokine-induced neovascularization principally
nvolves the small vessels including the vasa nervorum (180 m),
he nutrient vessels of peripheral nerves. Thus, transplanted
M-MNCs might have improved nerve perfusion and function
irectly by contributing to neovascularization, and indirectly by
ecreting a variety of angiogenic cytokines. In addition, because
ransplanted BM-MNCs presumably contain various kinds of
ells, such as bone marrow stromal cells, BM-MNC transplanta-
ion might have regenerated the damaged peripheral motor nerve.
This study has limitations. This study was an observational
pen-label study with no placebo control group. In addition, the
umber of patients enrolled in this study was small, and the
uration of the follow-up was short.
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henomenon or Syndrome Y
Microvascular Angina
waiting Recognition
r. Cannon is to be complimented on his important contributions
n the description of the elusive pathophysiology of microvascular
ngina. We would like to contribute to his otherwise excellent
eview (1) recently published in the Journal by making mention of
nother condition that also depends on an impairment in the
egulation of coronary microvascular resistances and that, there-romes. This condition, known as the coronary slow-flow phe-
omenon (CSFP), is increasingly recognized as a separate clinical
ntity along with the “classic” coronary syndrome X based on 3
egrees of evidence: 1) the coronary syndrome X and the CSFP
iffer mechanistically; 2) the CSFP has typical clinical features that
iffer strikingly from those of coronary syndrome X; and, finally, 3)
ts prognosis is not as benign as that traditionally described for
oronary syndrome X.
Although a number of formal definitions have been proposed,
he CSFP essentially consists of a delay in the progression of the
ontrast injected in the coronary vasculature during coronary
ngiography. Importantly, invasive studies have demonstrated that,
ompatible with the delayed opacification, resting coronary artery
esistances are abnormally elevated in these patients; in strikingnctioand N
Befor
89
.3
.9
.5
.5
.4
or unpa
0.01 veontrast with “classic” coronary syndrome X, however, these
